12月27日,加科思-B(01167)盘中上涨8.94%,截至15:59,报1.34元/股,成交229.39万元。加科思药业集团有限公司是一家专注于临床阶段新药研发,特别是创新肿瘤疗法的自主发现和开发的中国投资控股公司。其主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂,并主要在国内市场开展业务。截至2023年年报,加科思-B营业总收入6352.0万元、净利润-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.